Grand Pharma rises most in over a year as drug gets US FDA fast track designation
10/08/2026 04:41
BUZZ-Grand Pharma rises most in over a year as drug gets US FDA fast track designation ** Shares of Grand Pharmaceutical Group 0512.HK jump nearly 9% to HK$5.7, their highest level since May 20
** Stock on track for its biggest one-day pct rise since June 9, 2025
** Pharma group says its radionuclide-drug conjugate GPN01530-2 for diagnosis of solid tumours has recently been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA)
** FDA has established a Fast Track mechanism to expedite the review process for new drugs that treat serious or life-threatening diseases for which there are currently no effective treatments - co
** YTD, Hong Kong stock down 29.2%, while Hang Seng Biotech Index .HSBIO up 9.5%
(Reporting by Donny Kwok)
Recent news on Grand Pharmaceutical
See all newsBrief: Grand Pharmaceutical Group Declares No Interim Dividend Has Been Paid
Grand Pharmaceutical H1 revenue rises on nuclear medicine demand
Grand Pharma rises most in over a year as drug gets US FDA fast track designation
GPN01530-2 Granted Fast Track Designation By FDA
Brief: Grand Pharmaceutical Group Enters Huadong Medicine Supply Agreement